Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...

As you can see below, at the end of March 2024, Pfizer had US$69.9b of debt, up from US$36.2b a year ago. Click the image for more detail. However, it does have US$11.9b in cash offsetting this, ...

Pfizer Inc. announced on Thursday that it will move forward with the testing of its modified version of the once-daily weight ...

Investors with a lot of money to spend have taken a bullish stance on Pfizer PFE. And retail traders should know. We noticed ...

Pfizer inadvertently gave a leg up to two obesity biotechs yesterday with the announcement that an extended-release ...

One of the most notorious insider trading schemes in U.S. history has led to a $75 million fight between drugmaker Pfizer and ...

Pfizer announced that it is advancing its oral weight-loss treatment, called danuglipron, to the next round in an ongoing ...

Pfizer said it will continue to develop the once-daily version of its weight loss pill, danuglipron, after it saw ...

Pfizer announced that it has selected its preferred once-daily modified release formulation of danuglipron, a move that is ...

Pfizer is looking to challenge leaders Eli Lilly and Novo Nordisk in the fast-growing market for weight loss drugs. Pfizer ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on KalVista Pharmaceuticals (KALV – Research ...

Pfizer said it saw “encouraging” data from an ongoing early stage trial of its oral weight loss drug, danuglipron.